Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H22N4O7 |
Molecular Weight | 346.3364 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](OC)[C@H](O)CO
InChI
InChIKey=QNRRHYPPQFELSF-CNYIRLTGSA-N
InChI=1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1
Molecular Formula | C13H22N4O7 |
Molecular Weight | 346.3364 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18955520Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21973296 | http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006052.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18955520
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21973296 | http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006052.html
Laninamivir (R-125489), a new neuraminidase (NA) inhibitor, was discovered, and in this study, its NA inhibitory activities against various influenza viruses including oseltamivir-resistant viruses are reported. Laninamivir octanoate, has been approved for use in Japanese clinics for the treatment and prevention of influenza in both adults and children. The inhaled laninamivir octanoate is converted into its active form, laninamivir, in the lungs where a high concentration persists for a long period of time.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL6135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18955520 |
39.2 nM [IC50] | ||
Target ID: CHEMBL2051 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18955520 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | INAVIR Approved UseInavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate) is approved in Japan for the treatment and prevention of influenza in both adults and children. Launch Date2010 |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. | 2003 Dec |
|
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. | 2009 Nov |
|
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. | 2010 |
|
Antiviral strategies for pandemic and seasonal influenza. | 2010 Aug |
|
Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. | 2010 Nov |
|
Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. | 2010 Oct |
|
[Present and future in development of new anti-influenza drugs]. | 2010 Sep |
Patents
Sample Use Guides
1. For treatment of the influenza virus
Adults: A single inhaled dose of 40 mg of laninamivir octanoate
Children: If less than 10 years old, a single inhaled dose of 20 mg of laninamivir octanoate
If 10 years old or older, a single inhaled dose of 40 mg.
2. For prevention of the influenza virus
Adults and children over 10 years of age: Daily single inhaled dosage of 20 mg of laninamivir octanoate for two days
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18955520
Laninamivir (R-125489) neuraminidase inhibitory activity depends on virus strain. IC50 values lie in low nanomolar range.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:53:30 GMT 2023
by
admin
on
Sat Dec 16 17:53:30 GMT 2023
|
Record UNII |
B408IW3GL5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12791
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY | |||
|
9047
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY | |||
|
DTXSID60942457
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY | |||
|
C174629
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY | |||
|
Laninamivir
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY | |||
|
502272
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY | |||
|
203120-17-6
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY | |||
|
m6676
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
B408IW3GL5
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY | |||
|
100000140201
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY | |||
|
SUB89575
Created by
admin on Sat Dec 16 17:53:30 GMT 2023 , Edited by admin on Sat Dec 16 17:53:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|